R&D Pipelines Covering Various Therapeutic Areas
(As of 1 Sep 2023)

Pre Clinical		Phase I/II			Phase III	Approval for marketing/ Emergency use authorization
JS011 Undisclosed	**JS013** CD93	**JS006** TIGIT	**JS007** CTLA-4	**JS010** CGRP	**Bevacizumab** VEGF	**Toripalimab** PD-1
JS018 IL-2	**JS104** Pan-CDK	**JS009** CD112R	**JS014** IL-21	**UBP1213sc** BLyS	**Tifcemalimab** BTLA	**Adalimumab** TNF-α
JS114 Nectin4 ADC	**JS115** BCMA ADC	**JS015** DKK1	**JS105** PI3K-α	**JS103** Uricase	**Ongericimab** PCSK9	**Deuremidevir Hydrobromide Tablets** RdRp
JS120 IDH1	**JS121** SHP2	**JS107** Claudin18.2 ADC	**JS110** XPO1	**JS401** ANGPTL3	**JS005** IL-17A	**Etesevimab**[1]* S protein
JS122 FGFR2	**JS123** ATR	**JS111** EGFR exon 20	**JS112** Aurora A	**JS026** S protein		
JS205 EGFR x cMet	**JS206** IL-2 x PD-1	**JS113** EGFR 4th Gen	**JS116** KRAS			
JS208 Undisclosed	**JS211** PD-L1 x Undisclosed	**JS203** CD3 x CD20	**JS001sc** PD-1			
JS209 CD112R x TIGIT	**VV993** 3CL protease	**JS207** PD-1 x VEGF	**JS019** CD39			
JS008 Undisclosed	**JT109** Vaccine for Zika virus	**JS003** PD-L1	**JS012** Claudin18.2			
		JS101 Pan-CDK	**JS108** Trop2 ADC			
			JS201 PD-1 x TGF-β			

Oncology Metabolism Immunology Neurologic Infectious disease

*Received Emergency Use Authorization from the FDA

1. Etesevimab is expected to no longer generate revenue.
2. In August 2023, the Company conducted friendly negotiations with IMPACT Therapeutics, Inc.("IMPACT Therapeutics"). Based on the Company's commercial considerations, both parties have agreed to terminate their cooperation on Shanghai Junpai Yingshi Bio Pharmaceutical Co., Ltd. (the "JV Company") and the PARP inhibitor senaparib (code: JS109/IMP4297). Pursuant to the terms of the agreement, the Company will transfer its 50% equity interest in the JV Company to IMPACT Therapeutics, IMPACT Therapeutics will pay the corresponding share repurchase price to the Company.